Klin Onkol 2002; 15(3): 102-106.
Summary: Background. This retrospective study was initiated to assess the efficacy and safety of cefoperazone with sulbactam (Sulperazon) as an empirical therapy of febrile episodes in immunocompromised haematooncological patients. Patients and methods. Sixty hematooncological patients treated with Sulperazon at our department between March 2000 and July 2001 were analysed. The sensitivity tests of strains from isolated bacterias to various antibiotics including Sulperazon were determined. The efficacy rate of Sulperazon in clinical use was analysed as well. We also analyzed 696 positive findings from blood cultures from the patients hospitalized at our department in the year 2000. Results. In 28 patients, the daily dose of Sulperazon was 2 x 2g; in 32 patients, the daily dose was 3 x 2g. The total duration of administration of Sulperazon ranged from 3 to 22 days, with a mean of 9 days (median 9 days). In majority of patients, Sulperazon was administered with other antimicrobial drugs. In 38 patients, the criteria of febrile neutropenia were completed. No infection related death was observed in our patients. Adverse reactions unambiguously joined with usage of Sulperazon were not seen. Because of many severely ill patients studied, the frequency of some mild side effect may be underestimated, however. The Gram negative bacteria occupied 19 % of strains and Gram positive 81 % of strains from isolated bacteria from blood cultures. The results of susceptibility tests showed that 86 % of Gram negative bacteria isolates were susceptible to Sulperazon (100 % E. coli and Pseudomonas aeruginosa). Conclusion Therapy with Sulperazon represents a suitable choice for empirical antibiotic treatment of febrile episodes in hematooncological patients. Sulperazon demonstrated clinical safety and efficacy and can be used in combination with other drugs. It may be used, however, also as a monotherapy.
